AVDL:NSD-Avadel Pharmaceuticals plc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 8.07

Change

+0.30 (+3.86)%

Market Cap

USD 0.45B

Volume

0.32M

Avg Analyst Target

USD 17.00 (+110.66%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. The company's lead product candidate is FT218, a formulation of sodium oxybate which is in a Phase 3 clinical trial for the treatment excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-02 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
CGC Canopy Growth Corporation

-0.11 (-0.58%)

USD7.46B N/A N/A
APHA Tilray, Inc

N/A

USD6.86B 60.60 454.68
TLRY Tilray, Inc

N/A

USD6.56B N/A N/A
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
CRON Cronos Group Inc

-0.04 (-0.54%)

USD2.75B 37.00 N/A
PCRX Pacira BioSciences, Inc

+0.27 (+0.46%)

USD2.60B 17.73 37.25
IRWD Ironwood Pharmaceuticals, Inc

N/A

USD2.15B 14.93 12.02
ORGO Organogenesis Holdings Inc

-0.64 (-4.17%)

USD1.97B 41.46 30.47
SNDL Sundial Growers Inc

-0.01 (-1.26%)

USD1.53B -99,999.99 N/A

ETFs Containing AVDL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 20.81% 75% C 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.81% 75% C 70% C-
Trailing 12 Months  
Capital Gain -4.50% 47% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.50% 47% F 20% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 43.96% 85% B 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 43.96% 85% B 82% B-
Risk Return Profile  
Volatility (Standard Deviation) 161.59% 8% F 9% F
Risk Adjusted Return 27.20% 72% C- 43% F
Market Capitalization 0.45B 67% D+ 51% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 60.92 13% F 18% F
Price/Book Ratio 3.33 50% F 43% F
Price / Cash Flow Ratio -9.33 69% D+ 72% C-
EV/EBITDA 162.05 19% F 7% F
Management Effectiveness  
Return on Equity -6.59% 79% C+ 48% F
Return on Invested Capital -12.82% 57% F 31% F
Return on Assets -11.90% 54% F 25% F
Debt to Equity Ratio 79.01% 32% F 27% F
Technical Ratios  
Short Ratio 12.89 13% F 3% F
Short Percent 8.82% 43% F 22% F
Beta 1.31 46% F 39% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector